Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

2.35USD
26 May 2017
Change (% chg)

$0.33 (+16.34%)
Prev Close
$2.02
Open
$2.05
Day's High
$2.35
Day's Low
$1.93
Volume
415,218
Avg. Vol
256,215
52-wk High
$7.64
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

Elk Creek Partners reports 5.17 pct passive stake in Cerus as of May 4 - SEC filing
Monday, 8 May 2017 11:47am EDT 

May 8 (Reuters) - Elk Creek Partners : :Elk Creek Partners reports 5.17 percent passive stake in Cerus Corp as of May 4 - SEC filing.  Full Article

Cerus Corp reports Q1 loss per share $0.18
Wednesday, 3 May 2017 04:01pm EDT 

May 3 (Reuters) - Cerus Corp :Cerus Corporation reports first quarter 2017 results.Q1 loss per share $0.18.Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Cerus Corp - Product revenue recognized during Q1 of 2017 was $7.0 million compared to $7.6 million during same period in 2016.Cerus Corp - 2017 product revenue guidance to a new range of $43 million to 48 million.  Full Article

Cerus enters into supply and manufacturing agreement with Porex Corp
Monday, 17 Apr 2017 05:26pm EDT 

April 17 (Reuters) - Cerus Corp -:Cerus Corp - on April 13, co entered an amended, restated supply and manufacturing agreement with porex corp effective April 1, 2017 - SEC filing.Cerus Corp - entered amended agreement with porex corp to extend current supply and manufacturing agreement until December 31, 2019.  Full Article

Cerus reports Q4 loss per share of $0.13
Tuesday, 7 Mar 2017 04:01pm EST 

Cerus Corp : Cerus Corp reports fourth quarter and year end 2016 results . Q4 loss per share $0.13 . Q4 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S . Company expects 2017 global product revenue in range of $45 million to $50 million .Says product revenue for Q4 of 2016 was $10.1 million, compared to $9.7 million recognized during same period in 2015.  Full Article

Cerus Corp reports Q3 loss per share $0.14
Thursday, 3 Nov 2016 04:01pm EDT 

Cerus Corp : Continues to expect 2016 global product revenue in range of $37 million to $40 million . Cerus corporation reports third quarter 2016 results . Q3 loss per share $0.14 .Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Cerus announces first U.S. Blood center customer submits biologics license application
Thursday, 13 Oct 2016 08:30am EDT 

Cerus Corp : Cerus announces first U.S. Blood center customer submits biologics license application to the FDA to allow for interstate export of intercept platelet components .Cerus -community blood center of Appleton, Wisconsin has submitted first biologics license application to U.S FDA.  Full Article

FDA recommends use of pathogen reduction for universal Zika risk reduction of blood components
Monday, 29 Aug 2016 08:30am EDT 

Cerus Corp : Fda's new recommendation for universal zika risk reduction of blood components includes use of pathogen reduction .Use of pathogen reduction, such as intercept blood system for platelets and plasma, is specified as an acceptable safety measure.  Full Article

Cerus Q2 loss per share $0.18
Thursday, 4 Aug 2016 04:01pm EDT 

Cerus Corp : Q2 loss per share $0.18 . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Cerus corporation reports second quarter 2016 results . Q2 revenue $9.3 million versus i/b/e/s view $8.9 million . Sees fy 2016 revenue $37 million to $40 million .Fy2016 revenue view $38.7 million -- Thomson Reuters I/B/E/S.  Full Article

Cerus Corp signed multi-year purchase agreement for INTERCEPT Blood System
Tuesday, 9 Feb 2016 08:30am EST 

Cerus Corp:Says American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma.  Full Article

Cerus Corp announces agreement with Blood Systems Inc
Tuesday, 5 Jan 2016 08:30am EST 

Cerus Corp:Has signed a master agreement with Blood Systems Inc for use of INTERCEPT blood system for platelets and plasma.  Full Article

More From Around the Web

BRIEF-Cerus provides U.S. business update

* A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets